HUP0103432A2 - (3S)-Tetrahidro-3-furil-(1S,2R)-3-[[(4-aminofenil)-szulfonil]-(izobutil)-amino]-1-benzil-2-(foszfonooxi)-propil-karbamát-kalciumsó, valamint e vegyületet tartalmazó gyógyászati készítmény és eljárás e vegyület előállítására - Google Patents
(3S)-Tetrahidro-3-furil-(1S,2R)-3-[[(4-aminofenil)-szulfonil]-(izobutil)-amino]-1-benzil-2-(foszfonooxi)-propil-karbamát-kalciumsó, valamint e vegyületet tartalmazó gyógyászati készítmény és eljárás e vegyület előállításáraInfo
- Publication number
- HUP0103432A2 HUP0103432A2 HU0103432A HUP0103432A HUP0103432A2 HU P0103432 A2 HUP0103432 A2 HU P0103432A2 HU 0103432 A HU0103432 A HU 0103432A HU P0103432 A HUP0103432 A HU P0103432A HU P0103432 A2 HUP0103432 A2 HU P0103432A2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- formula
- calcium
- aminophenyl
- tetrahydro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 title abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 title abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title 2
- 229910052791 calcium Inorganic materials 0.000 title 1
- 239000011575 calcium Substances 0.000 title 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 title 1
- YNTOKMNHRPSGFU-UHFFFAOYSA-N n-Propyl carbamate Chemical compound CCCOC(N)=O YNTOKMNHRPSGFU-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
- 239000002904 solvent Substances 0.000 abstract 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 2
- 229910001424 calcium ion Inorganic materials 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 abstract 1
- 229960001830 amprenavir Drugs 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- RECVMTHOQWMYFX-UHFFFAOYSA-N oxygen(1+) dihydride Chemical compound [OH2+] RECVMTHOQWMYFX-UHFFFAOYSA-N 0.000 abstract 1
- 230000000865 phosphorylative effect Effects 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A tal lm ny t rgy t (I) képletű (3S)-tetrahidro-3-furil-(1S, 2R)- 3-[[(4-aminofenil)-szulfonil]-(izobutil)-amino]-1-benzil-2-(foszfono-oxi)-propil-karbam t-kalciumsó, valamint e vegyületet tartalmazó gyógyszati készítmény képezi; a tal lm ny t rgy hoz tartozik e vegyület Ikrist lyos alakj nak elő llít s ra szolg ló elj r s is. A krist lyostermék kedvező vízoldékonys got mutat, kül"n"sen 3 és 4 pH k"z"tt,ezért or lis bead sra alkalmas készítményekké alakítható. Atal lm nyszerinti elj r ssal elő llított termék vízoldékonys ga jobb mint azismert amprenaviré. Az (I) képletű vegyület eredményesen adhatóretrovírusok ltal előidézett betegségek kezelésére. Az (I) képletűvegyület oly módon llítható elő, hogy i) (II) képletű vegyületetfoszforilezőszerrel reag ltatnak, ii) az így kapott vegyületetmegfelelő oldószerben reduk lószerrel reduk lj k, és iii) az ígykeletkezett vegyülethez megfelelő oldószer jelenlé- tében kalciumion-forr st adnak. Az (I) képletű vegyület elő llít s nak m sik megold saszerint úgy j rnak el, hogy (III) képletű vegyületet megfelelőoldószerben feloldanak, majd az oldathoz vizet és kalciumion-forr stadnak. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815567.4A GB9815567D0 (en) | 1998-07-18 | 1998-07-18 | Antiviral compound |
| PCT/EP1999/004991 WO2000004033A1 (en) | 1998-07-18 | 1999-07-15 | Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0103432A2 true HUP0103432A2 (hu) | 2002-04-29 |
| HUP0103432A3 HUP0103432A3 (en) | 2003-01-28 |
| HU229700B1 HU229700B1 (en) | 2014-05-28 |
Family
ID=10835689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0103432A HU229700B1 (en) | 1998-07-18 | 1999-07-15 | Calcium salt of (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl)sulfonyl]-(isobutyl)amino]-1-benzyl-2-(phosphonooxy) propylcarbamate, pharmaceutical composition containing the compound and process for preparation the same |
Country Status (48)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
| CZ300031B6 (cs) * | 1999-10-06 | 2009-01-14 | Tibotec Pharmaceuticals Ltd. | Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl) (isobutyl)amino]-1-benzyl-2-hydroxypropyl}karbamát a farmaceutický prípravek s jeho obsahem |
| CZ302015B6 (cs) | 1999-10-08 | 2010-09-08 | Affinium Pharmaceuticals, Inc. | Inhibitory Fab I |
| ATE420640T1 (de) * | 2001-04-06 | 2009-01-15 | Affinium Pharm Inc | Fab-i-inhibitoren |
| KR100987815B1 (ko) * | 2002-04-26 | 2010-10-18 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 프로테아제 억제제 화합물의 포스포네이트유사체의 세포 축적 |
| DK1575951T3 (da) * | 2002-12-06 | 2014-09-15 | Debiopharm Int Sa | Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi |
| EP1608377B1 (en) | 2003-03-17 | 2008-10-01 | Affinium Pharmaceuticals, Inc. | Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
| CA2523083C (en) | 2003-04-25 | 2014-07-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| KR20060022647A (ko) | 2003-04-25 | 2006-03-10 | 길리애드 사이언시즈, 인코포레이티드 | 키나아제 억제 포스포네이트 유사체 |
| WO2004096287A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| EP1670448B1 (en) * | 2003-09-30 | 2007-11-21 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting sulfonamides |
| US7427624B2 (en) | 2003-10-24 | 2008-09-23 | Gilead Sciences, Inc. | Purine nucleoside phosphorylase inhibitory phosphonate compounds |
| WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| EP1678321A1 (en) | 2003-10-24 | 2006-07-12 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
| US20080287471A1 (en) | 2003-12-22 | 2008-11-20 | Maria Fardis | 4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity |
| SI1828167T1 (sl) * | 2004-06-04 | 2014-12-31 | Debiopharm International Sa Forum "Apres-Demain" | Akrilamidni derivati kot anitibiotična sredstva |
| PT1778251E (pt) | 2004-07-27 | 2011-06-29 | Gilead Sciences Inc | Análogos de fosfonato de compostos inibidores de vih |
| ES2537974T3 (es) | 2004-11-26 | 2015-06-16 | Ucl Business Plc | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática |
| WO2007067416A2 (en) * | 2005-12-05 | 2007-06-14 | Affinium Pharmaceuticals, Inc. | Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
| EP2054422B1 (en) | 2006-07-20 | 2017-06-14 | Debiopharm International SA | Acrylamide derivatives as fab i inhibitors |
| WO2008098374A1 (en) | 2007-02-16 | 2008-08-21 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab i inhibitors |
| JP5448854B2 (ja) | 2007-03-12 | 2014-03-19 | ウェルズ ファーゴ バンク ナショナル アソシエイション | オリゴマー−プロテアーゼ阻害剤複合体 |
| EP2262538B1 (en) * | 2008-03-12 | 2014-12-10 | Nektar Therapeutics | Oligomer-amino acid conjugate |
| CA2729769C (en) | 2008-07-08 | 2017-09-05 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
| SG174982A1 (en) | 2009-04-03 | 2011-11-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| US20120135965A1 (en) * | 2009-05-20 | 2012-05-31 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
| ES2517340T3 (es) | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
| WO2010144869A2 (en) | 2009-06-12 | 2010-12-16 | Nektar Therapeutics | Protease inhibitors |
| EP2448949A1 (en) | 2009-06-30 | 2012-05-09 | Ranbaxy Laboratories Limited | Crystalline form of fosamprenavir calcium |
| WO2011033469A1 (en) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Process for the preparation of fosamprenavir calcium |
| WO2011085130A1 (en) | 2010-01-07 | 2011-07-14 | Pliva Hrvatska D.O.O. | Solid state forms of fosamprenavir calcium salt and process for preparation thereof |
| US20120295898A1 (en) | 2010-01-27 | 2012-11-22 | Mark Richard Underwood | Antiviral Therapy |
| US20110224443A1 (en) * | 2010-03-15 | 2011-09-15 | Venkata Naga Brahmeshwara Rao Mandava | Preparation of fosamprenavir calcium |
| WO2011114212A1 (en) | 2010-03-19 | 2011-09-22 | Lupin Limited | Ammonium, calcium and tris salts of fosamprenavir |
| US20130211108A1 (en) | 2010-06-18 | 2013-08-15 | Mylan Laboratories Ltd | Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts |
| US8877947B2 (en) | 2010-09-10 | 2014-11-04 | Lupin Limited | Process for preparation of substantially pure fosamprenavir calcium and its intermediates |
| WO2012048043A1 (en) | 2010-10-06 | 2012-04-12 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
| CN102453054B (zh) | 2010-10-29 | 2015-06-10 | 浙江九洲药业股份有限公司 | 一种福沙那韦衍生物的制备方法及相关中间体 |
| CN102453053B (zh) * | 2010-10-29 | 2014-11-26 | 浙江九洲药业股份有限公司 | 一种福沙那韦钙晶体及其制备方法 |
| WO2012085625A1 (en) | 2010-12-21 | 2012-06-28 | Lupin Limited | Process for the preparation of fosamprenavir calcium and intermediate used in its preparation |
| WO2012107937A2 (en) * | 2011-02-10 | 2012-08-16 | Mylan Laboratories Ltd | Crystalline fosamprenavir calcium and process for the preparation thereof" |
| WO2013011485A1 (en) | 2011-07-20 | 2013-01-24 | Ranbaxy Laboratories Limited | Process for the preparation of sulfonamides useful as retroviral protease inhibitors |
| WO2013105118A1 (en) | 2012-01-10 | 2013-07-18 | Council Of Scientific & Industrial Research | A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir |
| MX356695B (es) | 2012-06-19 | 2018-06-11 | Debiopharm Int Sa | Profarmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)me til)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il) acrilamida. |
| KR20230018526A (ko) | 2014-11-24 | 2023-02-07 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
| CA2995823A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| KR20180114177A (ko) | 2016-02-26 | 2018-10-17 | 데비오팜 인터네셔날 에스 에이 | 당뇨병성 족부 감염의 치료제 |
| KR20200024145A (ko) | 2017-05-11 | 2020-03-06 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐아세테이트의 제조방법 |
| EP3960740B1 (en) | 2017-08-01 | 2023-11-15 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2698826A (en) * | 1951-02-13 | 1955-01-04 | Merco Centrifugal Co | Alcohol manufacturing process |
| US3437267A (en) * | 1966-03-24 | 1969-04-08 | Alfa Laval Ab | Centrifuge |
| JPH0244315B2 (ja) * | 1982-06-14 | 1990-10-03 | Microbial Chem Res Found | Supagarinn155hosufueetooyobisonoseizoho |
| US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
| WO1999033792A2 (en) * | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
| IL136940A0 (en) * | 1997-12-24 | 2001-06-14 | Vertex Pharma | Sulphonamide derivatives and pharmaceutical compositions containing the same |
| US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| GB9812189D0 (en) * | 1998-06-05 | 1998-08-05 | Glaxo Group Ltd | Methods and compositions for increasing penetration of HIV protease inhibitors |
| AU6329599A (en) * | 1998-09-28 | 2000-04-17 | Glaxo Group Limited | Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester |
| CN1154491C (zh) * | 1998-11-04 | 2004-06-23 | 法玛西雅厄普约翰美国公司 | 用于改善替普拉那维的药物动力学的方法 |
| CZ20002364A3 (cs) * | 1998-12-23 | 2000-11-15 | Vertex Pharmaceuticals Incorporated | Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje |
| GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
| DE60036961T2 (de) * | 1999-11-24 | 2008-08-28 | Merck & Co., Inc. | Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer |
-
1998
- 1998-07-18 GB GBGB9815567.4A patent/GB9815567D0/en not_active Ceased
-
1999
- 1999-07-14 DZ DZ990145A patent/DZ2845A1/xx active
- 1999-07-14 AR ARP990103446A patent/AR019388A1/es not_active Application Discontinuation
- 1999-07-14 GC GCP1999203 patent/GC0000105A/xx active
- 1999-07-15 AT AT99934698T patent/ATE229964T1/de active
- 1999-07-15 SV SV1999000096A patent/SV1999000096A/es not_active Application Discontinuation
- 1999-07-15 ID IDW20010145A patent/ID28070A/id unknown
- 1999-07-15 TN TNTNSN99145A patent/TNSN99145A1/fr unknown
- 1999-07-15 US US09/744,051 patent/US6514953B1/en not_active Expired - Lifetime
- 1999-07-15 EP EP02013136A patent/EP1240903A3/en not_active Withdrawn
- 1999-07-15 DK DK99934698T patent/DK1098898T3/da active
- 1999-07-15 PT PT99934698T patent/PT1098898E/pt unknown
- 1999-07-15 DE DE69904600T patent/DE69904600T2/de not_active Expired - Lifetime
- 1999-07-15 HU HU0103432A patent/HU229700B1/hu unknown
- 1999-07-15 PL PL99345620A patent/PL195736B1/pl unknown
- 1999-07-15 EP EP99934698A patent/EP1098898B1/en not_active Expired - Lifetime
- 1999-07-15 AU AU50379/99A patent/AU766056B2/en not_active Expired
- 1999-07-15 CA CA2337857A patent/CA2337857C/en not_active Expired - Lifetime
- 1999-07-15 EA EA200100053A patent/EA003191B1/ru not_active IP Right Cessation
- 1999-07-15 MY MYPI99002983A patent/MY122323A/en unknown
- 1999-07-15 GE GEAP19995716A patent/GEP20033030B/en unknown
- 1999-07-15 MA MA25684A patent/MA26660A1/fr unknown
- 1999-07-15 CZ CZ20010219A patent/CZ300447B6/cs not_active IP Right Cessation
- 1999-07-15 PE PE1999000714A patent/PE20000869A1/es not_active Application Discontinuation
- 1999-07-15 JO JO19992114A patent/JO2114B1/en active
- 1999-07-15 KR KR1020017000740A patent/KR100694721B1/ko not_active IP Right Cessation
- 1999-07-15 EE EEP200100038A patent/EE200100038A/xx unknown
- 1999-07-15 CO CO99044882A patent/CO5090836A1/es unknown
- 1999-07-15 ES ES99934698T patent/ES2189450T3/es not_active Expired - Lifetime
- 1999-07-15 TR TR2001/00111T patent/TR200100111T2/xx unknown
- 1999-07-15 OA OA1200100016A patent/OA11706A/fr unknown
- 1999-07-15 SK SK76-2001A patent/SK285311B6/sk not_active IP Right Cessation
- 1999-07-15 WO PCT/EP1999/004991 patent/WO2000004033A1/en active IP Right Grant
- 1999-07-15 IL IL14082499A patent/IL140824A/en not_active IP Right Cessation
- 1999-07-15 CN CNB998108383A patent/CN1188422C/zh not_active Expired - Lifetime
- 1999-07-15 YU YU3401A patent/YU3401A/sh unknown
- 1999-07-15 JP JP2000560139A patent/JP3437553B2/ja not_active Expired - Lifetime
- 1999-07-15 BR BRPI9912156A patent/BRPI9912156B8/pt not_active IP Right Cessation
- 1999-07-15 NZ NZ509291A patent/NZ509291A/en not_active IP Right Cessation
- 1999-07-15 GT GT199900111A patent/GT199900111A/es unknown
- 1999-07-15 AP APAP/P/2001/002039A patent/AP2001002039A0/en unknown
- 1999-07-16 PA PA19998477801A patent/PA8477801A1/es unknown
- 1999-08-06 TW TW088113428A patent/TWI245770B/zh not_active IP Right Cessation
-
2001
- 2001-01-12 IS IS5808A patent/IS5808A/is unknown
- 2001-01-15 ZA ZA200100417A patent/ZA200100417B/en unknown
- 2001-01-17 HR HR20010046A patent/HRP20010046A2/hr not_active Application Discontinuation
- 2001-01-17 NO NO20010282A patent/NO329676B1/no not_active IP Right Cessation
- 2001-02-14 BG BG105253A patent/BG105253A/xx unknown
- 2001-07-13 HK HK01104903A patent/HK1034261A1/xx not_active IP Right Cessation
-
2002
- 2002-11-25 US US10/303,366 patent/US20030096795A1/en not_active Abandoned
- 2002-11-25 US US10/303,213 patent/US20030100537A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0103432A2 (hu) | (3S)-Tetrahidro-3-furil-(1S,2R)-3-[[(4-aminofenil)-szulfonil]-(izobutil)-amino]-1-benzil-2-(foszfonooxi)-propil-karbamát-kalciumsó, valamint e vegyületet tartalmazó gyógyászati készítmény és eljárás e vegyület előállítására | |
| Murphy | Sulfhydryl group modification of sarcoplasmic reticulum membranes | |
| PT82949A (de) | Feste arzneimittelformen zur peroralen annendung enthalted 9-deoxo-11-deoxy-9,11-<imino<2-(2-methoxyethoxy)ethyliden>-oxy>-(9s)-erythromycin und verfahren zu ihrer herstellung | |
| JPH0434966B2 (hu) | ||
| RU2001101491A (ru) | Производные бензо (b) тиепин-1,1-диоксидов, способ их получения, содержащие эти соединения лекарственные средства и их применение | |
| RU94045950A (ru) | Фармацевтический препарат и способ его приготовления | |
| HUP0204114A2 (hu) | Bifoszfonáttartalmú parenterális gyógyászati készítmény | |
| JPH09508349A (ja) | 安定化オルトケイ酸含有調製物および生物学的調製物 | |
| HUP0102602A2 (hu) | Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| JPH06511008A (ja) | ヒト免疫不全ウイルス感染の治療方法 | |
| EP0327709A3 (en) | Novel platinum complex, antineoplastic agent containing the same, intermediate therefor, preparation method and use | |
| FR2455048A1 (fr) | Nouvelles 14-methoxymorphinane-6-ones, leur procede de production et medicament les contenant | |
| HUP9800512A2 (hu) | Moenomicin csoportba tartozó antibiotikumok bizmutsói, eljárás előállításukra, ezek alkalmazása és ezeket tartalmazó gyógyszerkészítmények | |
| ES482268A1 (es) | Un procedimiento para la preparacion del bis-(2-amonio-2- hidroximetil-1,3-propandiol)(2r-cis)-(3-metiloxiranil)-fos- fonato. | |
| HUT47599A (en) | Process for production of medical compositions containing as auxiliary material cyclopeptid | |
| JPH05501879A (ja) | Ｈｉｖおよび他のレトロウイルスを処理する方法およびそれに有用な化合物 | |
| TR200200147T2 (tr) | Yüksek saflıkta deramsiklan fumarat ve tuzlar, hazırlanmasına mahsus yöntem ve kullanımı | |
| EP0302836B1 (en) | Pharmaceutical compositions for topical use containing miocamycin | |
| WO2002069936A3 (en) | Pharmaceutical composition of ibuprofen | |
| PT1280812E (pt) | Ciclipostinas, processo para a sua preparacao e sua utilizacao | |
| IE873212L (en) | Medicaments based on derivatives of 3,4-di-phenylpiperidine,¹the use of the derivatives as medicaments, and novel¹3,4-diphenylpiperidine derivatives and a process for the¹preparation therefor | |
| HUP9801750A2 (hu) | Vízoldható B-polimixin-konjugátumok, eljárás azok előállítására és ilyen konjugátumokat tartalmazó gyógyszerkészítmények | |
| SE9202218D0 (sv) | Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation | |
| CA2347330A1 (en) | Liquid injectable formulation of disodium pamidronate | |
| KR960017680A (ko) | 포스포노술포네이트 스쿠알렌 합성 효소 억제제 염 및 그의 제조 방법 |